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vironmental health policy by building a coherent and sustainable framework and by increasing the
comparability of data across countries. A pilot study to test common guidelines for setting up surveys
was considered a key step in this process. Through a bottom-up approach that included all stakeholders,
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Study protocol1 http://www.eu-hbm.info/democophes (last accesse
Please cite this article as: Casteleyn, L., et
towards a common approach, challengesFrom September 2011 till February 2012, 17 European countries collected data from 1844 mother–
child pairs in the frame of DEMOnstration of a study to COordinate and Perform Human Biomonitoring
on a European Scale (DEMOCOPHES).1 Mercury in hair and urinary cadmium and cotinine were selected
as biomarkers of exposure covered by sufﬁcient analytical experience. Phthalate metabolites and Bi-
sphenol A in urine were added to take into account increasing public and political awareness for
emerging types of contaminants and to test less advanced markers/markers covered by less analytical
experience. Extensive efforts towards chemo-analytical comparability were included.
The pilot study showed that common approaches can be found in a context of considerable differ-
ences with respect to experience and expertize, socio-cultural background, economic situation and na-
tional priorities. It also evidenced that comparable Human Biomonitoring results can be obtained in such
context. A European network was built, exchanging information, expertize and experiences, and pro-
viding training on all aspects of a survey. A key challenge was ﬁnding the right balance between a rigid
structure allowing maximal comparability and a ﬂexible approach increasing feasibility and capacity
building. Next steps in European harmonization in Human Biomonitoring surveys include the estab-
lishment of a joint process for prioritization of substances to cover and biomarkers to develop, linking
biomonitoring surveys with health examination surveys and with research, and coping with the diverse
implementations of EU regulations and international guidelines with respect to ethics and privacy.
& 2014 Elsevier Inc. All rights reserved.2 http://ec.europa.eu/health/healthy_environments/working_groups/index_en.1. Introduction
Estimates of the impact of environmental exposures on health
are limited and contradictory. Part of the uncertainty lies in the
high level of misclassiﬁcation of exposures that hampers en-
vironmental health risk assessment (Weuve and Yonasky, 2012;
Willett, 2002; Blair et al., 2009). Scientists, policy-makers and the
general public have long focused mainly on external exposure
assessments for regulation and control. In analogy with practices
in occupational health and as technologies evolved, focus has now
increasingly turned to pollution in the body, seized by the notion
of body burden: the presence of chemicals in the body. Such body
burdens can be assessed through Human Biomonitoring (HBM),
which integrates information on exposure to potentially toxic
chemical elements and substances from all sources (soil, water, air,
food, packaging and consumer products) as well as bioavailability,
toxicokinetics and metabolism (Angerer et al., 2007). HBM and
other biomarker studies have shown their use in research, in
surveys and in advocacy efforts. Whilst research projects are ty-
pically hypothesis driven and geared at the collection of data to
link health outcomes causally to exposures, the objective of sur-
veys typically is to support and evaluate public health policy by
producing information on the prevalence of exposure to environ-
mental toxicants based on periodic monitoring (European Com-
mission, 2004; ECETOC, 2005; National Research Council of the
National Academies, 2006).
HBM is a powerful tool in the democratization of knowledge of
exposure. Personal exposure information in particular might have
a strong impact on societal perception of environmental pollution.
Human biomarkers data make pollution ‘personal’ and can raise
awareness, support preventive actions at individual and collective
level, and contribute to policy making (Stokstad, 2004). The full
exploitation of the potential beneﬁts of HBM surveys in environ-
mental health requires accurate knowledge transfer and integra-
tion. Findings of HBM efforts however, often fail to ﬁnd their way
into policy and practice, resulting in a limited impact on public
health policies and programs. Often single teams have proprietary
control of their data and specimens; the inner workings of pro-
tocols and analyzes are invisible to outsiders and raw data do not
become available (Khoury et al., 2013). HBM surveys increasingly
obtain a legal embedding at national or regional level, permitting
repeated cycles of measurement (Viso et al., 2009). In 2004, the
European Commission started discussions on a harmonized ap-
proach throughout Europe (European Commission, 2003; Eur-
opean Commission, 2004; Casteleyn et al., 2007) so to improved October 15 2014).
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and opportunities. Environcomparability. A European pilot study was proposed to “test the
hypothesis that human biomonitoring in the ﬁeld of environment and
health can be performed in a coherent and harmonized approach
throughout Europe by means of commonly developed protocols,
strategies and scientiﬁc tools ensuring reliable and comparable data,
whilst also leading to a more effective use of resources”. In an in-
terdisciplinary context, epidemiologists, chemists, toxicologists,
geneticists, exposure scientists, medical professionals, social sci-
entists and environmental health experts and policy makers,
working in the ﬁelds of environmental health, public health, re-
search and policy evaluation and support, worked closely together
to develop the framework. A stakeholders group set up by the
European Commission (European Commission, 2003)2 was in-
volved in this process. Study population, exposures and outcomes,
as well as parameters to be estimated, were partly deﬁned during
a broad negotiation process from 2004 until 2010. Finally a con-
sortium of scientists from 27 European countries completed the
decisions during the ﬁnal negotiation process from September
2010 until March 2011 and developed a common European HBM
study protocol, despite dissimilarities in approaches, technical
jargon, understanding of concepts and national priorities. An ex-
tensive exchange system was set up to take into account national
particularities, existing experience, expertize and infrastructure.
Organizations from 17 countries, all member of the consortium,
implemented the pilot study DEMOCOPHES.3 This article reports
on the opportunities and the challenges for a European harmo-
nization of HBM surveys in environmental health. It addresses the
set-up of a pilot feasibility study and related discussions on data
sharing, prioritization, linking with health examination, research
and policy. Finally, it also discusses ethics and privacy issues as the
transboundary nature of the study in a legal framework with di-
verse transpositions of EU regulations or of international guide-
lines into national laws was thought to be an additional obstacle
for harmonization of methodologies and comparability of results.2. A common study protocol
The common European study protocol was built in line with
STrengthening the Reporting of OBservational studies in Epide-
miology: Molecular Epidemiology (STROBE ME) guidelines (Gallo
et al., 2011) developed to facilitate reporting of biomarker-basedhtm (last accessed April 8 2014).
3 http://www.eu-hbm.info/democophes/project-partners (last accessed Octo-
ber 15 2014).
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Box 1–Table of contents of the European study protocol.
Fig. 1. Countries implementing the pilot study (in green): BE, CH, CY, CZ, DE, DK,
ES, HU, IE, LU, PL, PT, RO, SE, SI, SK, UK. (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the web version of this article.)
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guidelines relate to the collection, handling and storage of biolo-
gical samples; laboratory methods, validity and reliability of bio-
markers; speciﬁcities of study design; and ethical considerations.
Finally the protocol contains detailed provisions and procedures
for all stages of the study (see Box 1).
Due to the differences in registration governance, culture and
ethics, a rigid scheme of mandatory operational procedures for all
participating countries did not seem appropriate. Instead, the in-
dividual participating countries had the possibility to adapt certainPlease cite this article as: Casteleyn, L., et al., A pilot study on the feas
towards a common approach, challenges and opportunities. Environstudy elements in order to use existing resources and experience
insofar this would not jeopardize the comparability of the results
(Becker et al., 2014). Fig. 1 gives an overview of the countries that
implemented the pilot study.
The European consensus protocol was the basis for the ela-
boration of national protocols in each participating country. Each
country (i) set up a national team to implement the protocol,
headed by a so-called National Focal Point (NFP), gathering the
necessary expertize from own organizations and/or by hiring or
subcontracting; (ii) could add speciﬁc topics to the protocol, e.g. to
shed light on other topics of interest; (iii) had to adapt the back-
ground materials and questionnaires and translate them while
maintaining comparability. During the period September 2011 till
February 2012 this common European protocol was tested in the
ﬁeld to collect data from 1844 mother–child pairs in 17 countries
(Fig. 1). Table 1 gives an overview of the main activities in DE-
MOCOPHES as well as their projected and real timing. The protocol
is available at http://www.eu-hbm.info.
2.1. Selection of study participants, recruitment and ﬁeldwork
Children (age group of 6–11 years) were deﬁned as the primary
target group of the study with their respective mothers aged up to 45
years. Recruitment of 240 individuals (120 children and their mothers)
per participating country was anticipated, with an exception for the
two smallest countries where 60 mother–child pairs were required.
Recruitment and sampling was done from September 2011 until
February 2012. Different approaches were tested: 4 countries recruited
via the national population registries and 13 via schools. The mothers
were interviewed on environment and residence, nutrition, smoking
behavior, other exposure-relevant behavior, occupation and socio-
economic status (SES). Whenever possible, additional environmental
and health data were linked to the biomarker and questionnaire data
to improve interpretation of the results (Smolders et al., this issue).
Children and their mothers were recruited from minimum two dif-
ferent sampling locations according to the population density using
the upper and lower category (big city vs. rural) in each of the 17
countries implementing the pilot study, not including industrial sites.
The study protocol provided clear (examples of) standard operating
procedures (SOPs). Quality assurance methods for conducting the
ﬁeldwork included a Fieldwork Manual, active training programs for
interviewing and sampling, as well as internal and external quality
control measures. Data were collected using ﬁve questionnaires re-
lated to (i) recruitment, inclusion and exclusion criteria; (ii) sampling
of hair; (iii) sampling of urine; (iv) non-responding and
(v) information on nutritional and lifestyle behavior of mothers and
children participating in the study. Further details on the study designibility of European harmonized Human Biomonitoring: Strategies
. Res. (2015), http://dx.doi.org/10.1016/j.envres.2014.10.028i
Table 1
Gantt chart on the projected and real timing of the main activities in DEMOCOPHES.
Activities 2010 2011 2012 2013
Trimesters
4 http://www.eu-hbm.info/cophes/InformationworkshopanalyticsWP3
enviadaDIC2012.pdf (last accessed October 15 2014).
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learned on study design and ﬁeldwork are described by Fiddicke et al.,
this issue.
2.2. Biomarkers under investigation and biological sample handling
Mercury (Hg) in hair and urinary cadmium (Cd) and cotinine
were selected as biomarkers of exposure covered by sufﬁcient
analytical experience and knowledge on toxicokinetics. Phthalate
metabolites in urine were included to take into account currently
increasing public and political awareness for certain types of
contaminants and to test inclusion of less advanced markers
covered by less analytical experience. All seventeen countries
measured this limited set of biomarkers. Six of these countries
choose to measure urinary Bisphenol A (BPA) in addition. A com-
mon framework was established for the pre-analytical and ana-
lytical aspects. Pre-analytical SOPs included instructions and re-
commendations on sampling (material selection, material pre-
treatment) and how to collect the target biological matrices (urine
and hair), besides practical aspects like packing of samples, ship-
ment and preservation. For the analytical phase, SOPs were sug-
gested with instructions on the analysis of the DEMOCOPHES
biomarkers. A central element was the implementation of quality
assurance and control strategies. For the biomarkers chosen, ap-
propriate control/reference materials enabled the required inter-
nal quality assurance. External quality assurance was provided by
several External Quality Assessment exercises: two inter-labora-
tory comparison investigations (ICI) and two external quality as-
sessment schemes (EQUAS) (Schindler et al., 2014; Esteban et al.,
this issue). Effective capacity building was guaranteed trough webPlease cite this article as: Casteleyn, L., et al., A pilot study on the feas
towards a common approach, challenges and opportunities. Environmeetings discussing the results of the ICI and EQUAS programmes
and at a workshop on Quality of Analytical Data in Human
Biomonitoring”.4 This capacity building together with the strict
quality assurance and control process for the laboratories analyz-
ing the samples, made it possible to obtain comparable biomarker
measurements. Further details are described under ‘Sample pro-
cessing and QA’ at http://www.eu-hbm.info/COPHES and http://
www.eu-hbm.info/DEMOCOPHES. The post-analytical phase includes
storage of the biological samples for 10 years.
2.3. Data management and evaluation
A Statistical Working Group considered a number of issues with
respect to databases, data analysis and interpretation. To enable the
compiling of a single European database, all 17 partners implementing
the pilot study had to use the same database structure. Detailed in-
structions were provided in a codebook and in guidelines for quality
control. An automatic Quality Control (QC) process – programmed in
SAS software version 9.3 (SAS Institute Inc.) – was built in order to
facilitate the check of the data quality of the national databases before
merging them into one European database. The R code together with a
step-by-step manual and central support was provided to all NFPs.
Guidelines for rounding were provided for the correct handling and
processing of the biomarker values below the Limit of Quantiﬁcation
(LOQ). A Computer Assisted Personal Interview (CAPI) system was
tested for facilitating the ﬁlling of the questionnaires. For technicalibility of European harmonized Human Biomonitoring: Strategies
. Res. (2015), http://dx.doi.org/10.1016/j.envres.2014.10.028i
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CAPI was not always available – or for data protection reasons – the
data were temporally stored on a common database abroad – many
countries interviewed with the paper version and used the CAPI as a
data input system only. Questionnaire data and sample measurements
were processed as coded data. The European central database created
with these data contains no directly identiﬁable personal information
(e.g. address, name, etc.). Data Transfer Agreements were made be-
tween each individual partner implementing the pilot study and the
central database manager. These agreements prohibit disclosure of the
European pooled database inwhole or in part to any third party unless
agreed upon in writing by the partners providing the data. Individual
partners have the right to disclose their own data to others, in ac-
cordance with the ethics and privacy rules. After the end of this
agreement (in 2017) the European database manager has to destroy
the data received from each country and merged in the pooled Eur-
opean database, unless another agreement has been made with all
partners in the meantime. Approach and results of the statistical
analysis are described by Den Hond et al. (2015).
2.4. Communication strategy
Communication was essential throughout the pilot study, not just
limited to the informed consent procedure, but stretched out over
the recruitment, research and follow-up phases and playing at the
individual as well as the collective level. Guidelines for all commu-
nication steps, from initiation of the study to recruitment till dis-
semination of results, were included in the common protocol. Tem-
plates to facilitate harmonized approaches were provided. Because of
ethical and democratic rules, European individuals are entitled to be
informed on uses, users and results related to their samples and data
(Casteleyn et al., 2010). Templates for reporting results to the in-
dividual study participants contained information on the health re-
levance of the data. The fact sheets also included recommendations
for individual exposure reduction. Actions at community level and
participatory approaches were encouraged. Process, material and
results are described in more detail in this special issue (Exley et al.,
this issue). To inform and engage not only scientists, but also pol-
icymakers, authorities, NGO’s and industry of the preliminary results
and conclusions of the pilot study, they were presented at a con-
ference held in the framework of the Presidency of the European
Union (Cyprus Presidency Conference, 2012). Between October 2012
and June 2013, each of the 17 countries organized a national sym-
posium to report on the aggregated results to the general public and
to their policymakers, often with a lot of media attention.5 Topics of
particular interest included relevance and use of HBM results for
policies and in actions at national level, feasibility of a European
harmonized program and the next steps required in line with both
the European Environment and Health Action Plan 2004–2010
(European Commission, 2004) and the WHO Parma Declaration on
Environment and Health, 2010 (WHO, 2010).
2.5. Training
All partners implementing the pilot study, some of them lacking
established resources and capable staff, were assisted. Following a
‘train the trainer approach’, national team coordinators were trained
during two workshops. Sessions were organized for ﬁeldworkers and
check lists were provided for internal quality control. The External
Quality Assessment exercises mentioned above were considered as a
training activity. The ICI/EQUAS rounds provided opportunities to
check and improve the analytical methods and ensure the compar-
ability of the analytical results. The web conferences, held after each5 http://www.eu-hbm.info/euresult/media-corner (last accessed May 13 2014).
Please cite this article as: Casteleyn, L., et al., A pilot study on the feas
towards a common approach, challenges and opportunities. Environexercise, allowed for an exchange of experiences between the parti-
cipating laboratories and the organizers of the ICI/EQUAS. Two training
sessions on database management, quality control of the data and
statistical analysis were organized. More information on the training
provided can be found at http://www.eu-hbm.info under ‘Training’.2.6. Ethics and data protection
Guidelines for the preparation of the ethical forms and for the
notiﬁcation to privacy authorities were given in annexes of the
protocol. Forms to be submitted for ethical approval and notiﬁ-
cation to the national privacy authorities, although following a
similar logic, differ from country to country. Therefore the prac-
tical preparation of the ethical forms and privacy notiﬁcation was
complemented by a system of exchange of experiences, bilateral
contacts, and templates. Direct questions could be answered via
the helpdesk. Details on ethics committees, privacy regulations,
right to know, and secondary use is given below.2.7. Feasibility of a European framework and program
A common approach for HBM was tested in 17 European countries.
The main objective was to build a coherent and sustainable framework
for HBM surveys in Europe and increase the comparability of data
across countries. Testing of common guidelines for setting up surveys
was considered a key step in this process. These guidelines, included in
a common study protocol, were elaborated trough a bottom-up ap-
proach, engaging all participating countries to facilitate compliance,
despite huge differences in cultural, social, economic background, ex-
perience and expertize. Financial means were restricted, and the
number of samples was therefore limited. The pilot study convincingly
showed that comparable HBM results could be obtained in 17 Eur-
opean countries all implementing the same study protocol, with little
adaptations and with extensive efforts towards chemo-analytical
comparability. Biomarker data and questionnaire data informed on
exposure to a limited set of substances (Hg, Cd, tobacco, phthalates and
in six countries BPA) and gave insights on exposure sources. For the
ﬁrst time, the results obtained are comparable on a European scale,
which is a step towards European reference values. A European net-
work was built, exchanging information, expertize and experiences,
providing training facilities at several levels. The common approach to
HBM allowed (i) testing the tools and protocols developed; (ii) gen-
erating for the ﬁrst time comparable data for selected substances; and
(iii) providing recommendations for further studies and programs. Key
challenges in determining common approaches were ﬁnding the right
balance between a rigid structure allowing maximal comparability and
a ﬂexible approach increasing feasibility and allowing capacity building.
The discussions underpinning the pilot study revealed also
further challenges and opportunities for next steps. Stakeholders
expressed several demands for a European HBM program. These
included ‘obtaining preliminary reference values of selected biomarkers
from all participating Member States’; testing out linking of HBM values
with environment and health indicators; and establishing protocols for
the translation of HBM results into policy recommendations.6 Whilst
these challenges are already tackled at national level in a few Eur-
opean countries as discussed below, a global European approach is
not yet established and needs further phases.6 http://www.eu-humanbiomonitoring.org/doc/ig_rec3.pdf (last accessed May
13 2014).
ibility of European harmonized Human Biomonitoring: Strategies
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3.1. Reference values
One of the aims of setting up HBM surveys is to gain knowledge
of the background exposure of the population under study and
establish reference values. These are required by policymakers and
researchers to support their work. Together with information on
health based guidance values, which are totally different in scope
and use, such reference values are deemed essential for inter-
pretation and communication of results and for translation into
preventive policies. Although deﬁnitions may differ among stu-
dies, reference values are often described as statistically derived
values of the 95% conﬁdence intervals of estimated 95th popula-
tion percentiles and indicate the upper margin of background
exposure to a given pollutant in a given population at a given time.
Recommendations on standardized biological reference values
have been published by the International Organization for Stan-
dardization (ISO) and the International Federation of Clinical
Chemistry (IFCC). They can be used to identify subjects with an
increased level of exposure (in relation to background exposure) to
a given environmental toxin. However, they do not represent
health-related criteria for the evaluation of HBM data (Ewers et al.,
1999). Reference values for environmental pollutants are estab-
lished at national level in several countries and reported in peer
reviewed publications. For instance, for Germany by the Human
Biomonitoring Commission of the German Federal Environment
Agency, based on representative population data collected in re-
petitive rounds within the GerES program (Conrad et al., 2013); for
France by the ‘Institut de Veille Sanitaire’ based on representative
population data collected by ENNS (Etude Nationale Nutrition
Santé), the French Nutrition & Health Survey7; for Flanders
(northern part of Belgium) by the Flemish Center of Expertize for
Environment and Health, based on representative population data
collected in the Flemish Environment and Health Surveys (FLEHS I
2002-2006, FLEHS II 2007–2011) (Schoeters et al., 2011); for the
Czech Republic by the Environmental Health Monitoring System
(EHMS) (Cerná et al., 2007); for Slovenia by The National Chemi-
cals Bureau of The Ministry of Health (Horvat et al., 2012; Snoj
Tratnik et al., 2012), for Spain by the BIOAMBIENT.ES study im-
plemented by the Institute of Health Carlos III (Pérez-Gómez et
al.,2012), for Italy by the Program for biomonitoring the Italian
population exposure PROBE implemented by the National Institute
for Health,8 for Canada by the Canadian Health Measures Survey
(Haines and Murray, 2012) and for the United States by the Human
Biomonitoring part of NHANES, the US National Health and Nu-
trition Examination Survey (Calafat, 2012). In the European pilot
study the number of samples was too small to be representative
and the data obtained do not fulﬁll the scientiﬁc criteria for a
“reference” base. They are to be seen as preliminary values.
However, the sample size was considered to be sufﬁciently large to
allow (minimal) statistical evaluations with 'preliminary' reference
values for the groups chosen. For the further development of a
common European HBM approach the current effort needs to be
expanded to (i) measuring exposure to a larger number of sub-
stances and (ii) obtaining data from a suitable reference population,
representative for the European population.7 Institut de Veille Sanitaire, http://www.invs.sante.fr/Dossiers-thematiques/
Maladies-chroniques-et-traumatismes/Nutrition-et-sante/Enquetes-et-etudes/
ENNS-etude-nationale-nutrition-sante (last accessed April 8 2014).
8 http://www.iss.it/binary/publ/cont/11_9_web.pdf (last accessed October 15
2014).
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A broad list of chemical substances or their metabolites, from all
major categories contributing to the individual’s exposure, can be
measured in blood, urine or other biological matrices. For a more
comprehensive assessment of exposure at European level, the
substances to address will have to be identiﬁed through a trans-
parent process of prioritization. Such processes have been devel-
oped at national level in several countries, and follow basically si-
milar lines with evaluation of needs, inclusion of participatory ap-
proaches, etc. In the French national biomonitoring program for
instance, the selection of compounds for the ESTEBAN survey was
based on the feasibility of Human Biomonitoring, toxicity and re-
levance (regulations and policy priorities). They were grouped
based on chemical properties, toxicity, and analytical techniques. A
modiﬁed Delphi method was used for the prioritization of sub-
stances. Criteria for scoring were health hazard, exposure levels,
social perception, biomarker characteristics, interpretability of the
results in terms of health risk, logistic and analytical feasibility,
exposure prevention/reduction feasibility, and contributions to
closing knowledge gaps (Filliol et al., 2014). In NHANES, selection
criteria for chemical substances that have been used include af-
fordability, availability of adequate analytical methods, easy sam-
pling or availability of sample matrices, toxicological properties,
suspected exposure levels, seriousness of health effects known or
suspected to result from some levels of exposure and the need to
assess the effectiveness of public health actions to reduce exposure
to a chemical. The availability of biomonitoring methods with
adequate performance and acceptable cost is a major consideration.
The selection of substances is performed via the Federal Registry,
enabling any person, entity or corporation to nominate a substance.
Moreover, speciﬁc criteria have been developed to remove a sub-
stance from the survey. Details on the prioritization process for
scoring nominated chemicals and the resulting scores are available
at their website.9 In Flanders, prioritization of biomarkers for in-
clusion in the HBM program was based on criteria such as pro-
duction volume, legal framework to regulate the chemical, expected
exposure route for the general population, (highest) exposed group,
vulnerable age group, expected health hazard, lowest exposure le-
vel associated with adverse health effects, estimated daily intake
levels, guidance values for external/internal exposure, estimated
margin of safety in relation to Lowest Observed Adverse Effect Level
(LOAEL) or Tolerable Daily Intake (TDI), biological half-life in hu-
mans, risk for perinatal exposure, biological matrix needed for
monitoring, sample volume needed for bioassay analysis, limit of
detection of the biomarker value, costs, validation status of the
biomarker and experience within the consortium (Steunpunt Milieu
en Gezondheid, 2011). In Germany, three out of six chemicals to be
authorized or banned from 2015 due to REACH regulations were
identiﬁed as relevant chemicals by the German HBM system as
GerES exposure data showed that they exceeded tolerable daily
intakes in a considerable fraction of children living in Germany. In
addition to chemicals identiﬁed as problematic in toxicological or
exposure studies, a list of chemicals suggested as HBM candidates of
high priority in view of consumer protection was established by the
German Federal Scientiﬁc Agencies. This list includes chemicals
used in cosmetics, contaminants in food, additional phthalates,
phthalate substitutes, aromatic amines, benzothiazoles, musk fra-
grances, ﬂuorinated and perﬂuorinated compounds, ﬂame re-
tardants, SVHC candidates (Substance of Very High Concern, REACH
Art. 57) and corrosion inhibitors (Kolossa‐Gehring et al., 2011).9 http://www.cdc.gov/exposurereport/chemical_selection.html (last accessed
December 2014).
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A basic requirement for deriving HBM assessment values for
speciﬁc substances is the identiﬁcation of a speciﬁc and analyti-
cally traceable biomarker. A primary requirement is that an ana-
lytical method exists (or can be developed) to provide reliable
measurements of the biomarker in biological media. Several ad-
ditional characteristics contribute to the usefulness of potential
biomarkers, including stability, speciﬁcity and invasiveness of
sampling. As mentioned before, besides adequate performance,
acceptable cost is a major consideration in the prioritization of
substances to address in a survey program. For many substances
suitable biomarkers are available. For emerging substances how-
ever, methods need to be developed and for this as well prior-
itization is needed, through a transparent process. In this context,
the German Federal Ministry for the Environment, Nature Con-
servation, Building and Nuclear Safety (BMUB) and the German
Chemical Industry Association (VCI), currently work together. VCI
assumes the responsibility and the funding for developing the new
chemical–analytical methods; BMUB uses them to apply popula-
tion-based HBM studies. Emphasis is placed on substances with
either potential health relevance or to which the general popula-
tion might potentially be exposed to a considerable extent. The
work is supported by an advisory panel consisting of scientists
from academia, industry and administration. Strategic decisions
are made by a management committee including representatives
from industry, the Ministry, and the Federal Environment Agency
(Kolossa-Gehring and Becker, 2011). To our knowledge no similar
initiatives exist in Europe for a transparent participatory process
to identify further research needs in developing human
biomarkers.12 http://www.projecthelix.eu/ (last accessed October 15 2014).3.4. Linking HBM surveys with health surveys and with
research
National and international funders increasingly demand op-
erational linkage of HBM surveys with health examination surveys.
High-quality health surveys are on-going in Europe, such as the
European Health Interview Survey (EHIS),10 which enquires about
background information, including SES, health status, health
determinants and (use of) health services (Eurostat, 2010), and
the local WHO MONICA studies, which monitor trends in cardio-
vascular diseases.11 In addition, the EU funded European Health
Examination Survey project (EHES) was a collaboration to collect
health data, comparable between countries and over time (Kuu-
lasmaa et al., 2012). However, the health survey initiatives suffer
from difﬁculties with sustainability and a legal basis has only been
adopted for EHIS. Developing a framework for combining exposure
and health assessment in an integrated survey at European level
using harmonized and quality controlled protocols is one of the
future challenges. Several integrated approaches are already run-
ning in Europe and elsewhere. The USA’s NHANES assesses the
health and nutritional status of adults and children in the United
States and also gathers a wealth of data, representative of the
entire population’s exposure to pollutants. The Canadian Health
Measures Survey (CHMS) collects information from Canadians
about their general health and includes measurements of chemi-
cals in blood and urine samples. In Europe, Germany (Schulz et al.,
2007), the Czech Republic (Cerná et al., 2012) and Slovenia (Horvat
et al., 2012) perform health examination surveys combined with10 http://epp.eurostat.ec.europa.eu/portal/page/portal/product_details/publica
tion?p_product_code¼KS-RA-13-018 (last accessed May 14 2014).
11 http://www.thl.ﬁ/monica/ (last accessed April 11 2014).
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an integrated (HBM coupled with nutrition and health studies)
multi-pollutant approach. This approach has been initiated in
France with a national population-based biomonitoring survey, the
‘Etude nationale nutrition santé’ (ENNS; French national survey on
nutrition and health). This survey provided the ﬁrst reference
distribution for 42 biomarkers in the French population. The cur-
rent national HBM strategy builds upon the ENNS and includes a
national survey of people aged between 6 and 74 years com-
plemented for the neonatal period and childhood by the ‘Etude
Longitudinale Française depuis l’Enfance’ (ELFE; French long-
itudinal study of children) (Fréry et al., 2012).
Many biomarkers of exposure used in HBM programs address
single chemicals one at a time and are limited in respect to vali-
dation and integration with health outcomes. Much research is
needed for improved understanding of environment–health–dis-
ease associations and their underlying mechanisms. More recently
developed biomarkers (i.e. omics-derived biomarkers) offer great
promise in reﬁning exposure estimates and establishing biological
plausibility of exposure-disease associations. These markers re-
present a continuum of cellular responses to drug or chemical
exposures and provide linkages to mechanisms of cell injury/cell
death or carcinogenic transformation. Recent EU-funded projects
such as Human Early-Life Exposome (HELIX)12; EXPOsOMICS13;
Health and Environment-wide Associations based on Large po-
pulation Surveys (HEALS)14 and Cross-Mediterranean Environ-
ment and Health Network (CROME)15 attempt to link collected
exposure data to biochemical and molecular changes in our body
so to improve our understanding on how these pollutants inﬂu-
ence the risk of developing chronic diseases. They apply the ex-
posome concept, a novel approach to studying the role of the
environment in human disease, which refers to the totality of
environmental exposures from conception onwards. However,
application for risk assessment in public health is still limited due
to implementation, validation and interpretation issues (Wild,
2005; Smith et al., 2005; Vineis et al., 2011; Rappaport, 2012; Wild,
2011). The combination of traditional methods for assessment of
individual exposure through cross sectional surveys with these
omics techniques might be an opportunity to forward the devel-
opment of preventive strategies. Data on chemical exposures that
have not been hypothesized a priori as having an impact on health
may be generated and patterns or individual proﬁles that go be-
yond single chemical approaches may be identiﬁed. Follow up
studies in which the individual health and disease status is further
monitored should allow identifying biomarkers and individual
molecular proﬁles that are predictive of disease risk. The hy-
potheses thus generated, have to be further investigated in nested
case-control studies in existing longitudinal cohorts (Vineis and
Perera, 2007).3.5. Knowledge transfer and integration
Environmental health is a sensitive issue in society. Both at
collective and at individual level information on exposure and
burden of disease is required. The public at large and policymakers
want to evaluate related policies such as the Regulation on clas-
siﬁcation, labeling and packaging of substances and mixtures,16
the Regulation (EC 1907/2006) on the Registration Evaluation and13 http://www.exposomicsproject.eu/mission (last accessed October 15 2014).
14 http://www.heals-eu.eu (last accessed October 15 2014).
15 http://www.crome-life.eu/ (last accessed October 15 2014).
16 http://ec.europa.eu/enterprise/sectors/chemicals/classiﬁcation/index_en.
htm (last accessed May 13 2014).
ibility of European harmonized Human Biomonitoring: Strategies
. Res. (2015), http://dx.doi.org/10.1016/j.envres.2014.10.028i
L. Casteleyn et al. / Environmental Research ∎ (∎∎∎∎) ∎∎∎–∎∎∎8Authorization of Chemicals17, the Strategic Approach to Interna-
tional Chemicals Management (SAICM),18 the OECD Cooperative
Chemicals Assessment Program,19 the Stockholm Convention on
POPs,20 the Regulation (EC 1107/2009) on the placing of plant
protection products on the market,21 the Regulation (EU 528/2012)
on biocidal products,22 the EU Cosmetics Directive (EU, 1976), and
the EU Directive on chemical agents at work (EU, 1998). Also,
European regulatory agencies and committees involved in risk
assessment need more information on European exposure. The
agencies and committees involved are the European Food Safety
Agency,23 the European Environment Agency,24 the European
Medicines Agency25 and the European Chemicals Agency26 as well
as the independent Scientiﬁc Committees advising on proposals
relating to consumer safety, public health and the environment.27
However, access to data is not always straightforward: tradition-
ally single research teams have proprietary control of their data
and specimens. Protocols, analyzes and raw data are often not
directly available. The European approach anticipated a maximal
potential broad availability of data, protocols and analyzes from
the pilot study despite legal, ethical or pragmatic reasons that may
hinder full transparency. Information at layman’s level was pro-
vided in 15 languages at the national28 and European29 websites of
the pilot study.
In the EU Environment and Health Strategy, special con-
sideration was asked for an accurate translation to policy. Data
generated should bear relevant and useful information for risk
managers and policymakers in terms of developing, adapting and
evaluating environmental policies (Smolders et al., 2008). Despite
its nature of pilot study with obvious limitations in substances and
population covered, data from the DEMOCOPHES pilot study so far
assisted with research on the economic calculation of the cost of
the actual exposure of Europeans to mercury, which supported the
UNEP discussions on measures to reduce exposure to this wide-
spread heavy metal (Bellanger et al., 2013). The methodology
tested also supported the important efforts by WHO for a har-
monized generation of HBM data in the WHO European region,
with a broader coverage of 53 countries. The Parma Declaration on
Environment and Health, adopted at the 5th Ministerial Con-
ference on Environment and Health in 2010, calls for the in-
tensiﬁcation of actions by the Member States of the WHO Eur-
opean Region to protect children’s health from environmental
hazards, such as harmful chemicals including carcinogens, muta-
gens, reproductive toxicants and endocrine disruptors. The Parma
Declaration speciﬁcally recognized pregnant and breast-feeding
women as target population groups for actions aimed at identi-
fying and reducing environmental risks as far as possible by 2015.
The Member States also committed themselves to developing a17 http://ec.europa.eu/enterprise/sectors/chemicals/reach/index_en.htm (last
accessed May 13 2014).
18 http://www.saicm.org/ (last accessed May 13 2014).
19 http://www.oecd.org/chemicalsafety/risk-assessment/oecdcooper
ativechemicalsassessmentprogramme.htm (last accessed May 13 2014).
20 http://chm.pops.int/Implementation/GlobalMonitoringPlan/MonitoringActiv
ities/tabid/181/Default.aspx (last accessed May 13 2014).
21 http://europa.eu/legislation_summaries/food_safety/plant_health_checks/
sa0016_en.htm (last accessed May 13 2014).
22 http://echa.europa.eu/regulations/biocidal-products-regulation (last ac-
cessed May 13 2014).
23 http://www.efsa.europa.eu/ (last accessed May 13 2014).
24 http://www.eea.europa.eu/ (last accessed May 13 2014).
25 http://www.ema.europa.eu/ema/ (last accessed May 13 2014).
26 http://echa.europa.eu/regulations/biocidal-products-regulation (last ac-
cessed May 13 2014).
27 http://ec.europa.eu/health/scientiﬁc_committees/about/index_en.htm%20
(last accessed May 13 2014).
28 http://www.eu-hbm.info/democophes/project-partners (last accessed May
13 2014).
29 http://www.eu-hbm.info/democophes (last accessed May 13 2014).
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as a complementary tool for evidence-based public and environ-
mental health measures. In order to enable efﬁcient monitoring of
the progress towards these time-bound goals, the WHO European
Center for Environment and Health (ECEH) has been coordinating
the development of biomonitoring-based indicators. Early life ex-
posure to mercury and polybrominated diphenyl ethers (PBDEs)
were identiﬁed as the most relevant biomonitoring-based in-
dicators of exposure supplementing the HBM-based indicators
blood lead level in children and dioxins in human milk, which
have already been implemented in WHO’s European Environment
and Health Information System (ENHIS) (WHO, 2010; Egorov,
2012).
It is increasingly acknowledged that communication in HBM
needs speciﬁc skills and support of appropriate expertize to ad-
dress the questions of what is to be communicated, to whom,
under which form, and at what time (Casteleyn et al., 2010). Par-
ticular challenges are for example in transferring messages with a
scientiﬁc and technical content to an audience with no back-
ground in science and to explain the uncertainties. In addition,
participatory approaches are becoming incorporated in HBM sur-
veys (Morello-Frosch et al., 2009, 2014). The answers to these
challenges might inﬂuence the success of future survey programs.
Good communication will increase trust and conﬁdentiality in
research and impact participatory rates (Halkoaho et al., 2012).4. Ethics and privacy: an obstacle?
The donation of tissues or ﬂuids by healthy volunteers implies
sensitive ethical and privacy questions. To ensure the protection of
the rights and dignity of study participants a complex legal and
ethical framework exists in Europe. One of the most important
international references to deﬁne and safeguard fundamental
human rights in the ﬁeld of biomedical research, in particular of
those participating in research, is the Oviedo Convention30 and its
Additional Protocol concerning Biomedical Research.31 They set
out the fundamental principles applicable in day-to-day medicine
as well as those applicable to new technologies in human biology
and medicine. The Oviedo Convention is an international con-
vention. Its action extends to all countries that have ratiﬁed it. The
Oviedo Convention has currently been signed by 34 Member
States of the Council of Europe, of which 21 have so far also ratiﬁed
the Convention.32 Ten of the 17 countries of the pilot study have
ratiﬁed the Oviedo Convention. The European Court of Human
Rights uses the Oviedo Convention as an expression of European
human rights standards, even in cases involving countries that
have not signed or ratiﬁed the convention. The Additional Protocol
on biomedical research entered into force after ﬁve ratiﬁcations on
01/09/2007. Of particular relevance for the pilot study was the
question whether the diverse implementations of EU regulations
or of international guidelines into domestic law would hinder the
harmonization of methodologies and the comparability of results.
4.1. Ethics committees
The Additional Protocol emphasizes the necessity of obtaining
informed consent and requires that a research project is submitted
to an ethics committee for independent examination of its30 http://conventions.coe.int/Treaty/en/Treaties/Html/164.htm (last accessed
May 13 2014).
31 http://conventions.coe.int/Treaty/en/Treaties/Html/195.htm (last accessed
May 13 2014).
32 http://conventions.coe.int/Treaty/Commun/ChercheSig.asp?
NT¼164&CM¼&DF¼&CL¼ENG (last accessed May 13 2014).
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Table 2
Time for approval by ethics committees and for replies by privacy authorities.


















Approval Ethics: 0 days means that approval was received the day of formal sub-
mission.
Notiﬁcation Privacy: 0 days means that data protection issues were included in the
application to the ethics committee or that no answer from the privacy authorities
was required.
All of the actions took place between December 2010 and February 2012.
n Approval under conditions; ﬁnal approval 112 days later.
nn General notiﬁcation was included in the application to the ethics committee,
but to obtain address data from the inhabitants register a notiﬁcation had to be
sent to each municipality were subjects were recruited since data protection was
managed at municipal level.
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ability. All countries participating in the pilot study needed ap-
proval from an ethics committee. The time needed to obtain ap-
proval varied strongly between countries and situated in the range
from 0 – in one country the study proposal was submitted and
clariﬁed to the ethics committee at their meeting and approval
was obtained the same day – to 113 days. Table 2 gives an over-
view of the time needed.
Most frequently requested documents are a summary of the
protocol (in English), the informed consent form (in local lan-
guage) and all documents related to communication to the parti-
cipants (in local language). In four countries the curriculum vitae
of the investigators were requested. One ethics committee also
required a statement of no conﬂict of interest of the collaborators.
In one country a General Practitioner (GP) booklet was required
advising GPs on the study and providing information on the fol-
low-up management of participants, including whether repeat
testing of the chemicals under study was required. In this case, all
GPs in the local area where the sampling occurred were sent a
brochure. Also an external auditor (Medical Doctor) to whom
participants could communicate any complains or worries had to
be appointed. In two countries the ethics committee stressed that
those who respond that they do not want to participate cannot be
pressed into completing a non-responder questionnaire. Table 3
gives an overview of the documents submitted in English and/or
translated into local language.
4.2. Data protection
The Data Protection Directive 95/46/EC regulates the proces-
sing of personal data within the EU.33 It places obligations on or-
ganizations using personal information and gives individuals cer-
tain rights. Samples and data obtained in a Human Biomonitoring
study are considered sensitive personal data related to health.
Processing of such data is in principle forbidden, unless certain
conditions are met. Scientiﬁc research and government statistics
are stated to be “of important public interest” and are facilitated.
In the pilot study, samples and data were coded for processing.
The directive states that those who record and use personal data
must be open about how the information is used and must follow
the principles of ‘good information handling’ laid down in the
Directive. The Data Protection Directive imposes the practice of
informed consent, including the right to know one’s own in-
dividual results, and notiﬁcation of the research to the national
data protection supervisory authority. Although the Data Protec-
tion Directive is implemented in all EU member states, signiﬁcant
differences in practices exist between countries. Six countries
declared that notiﬁcation was not required, because data protec-
tion issues are included in the applications to the ethics commit-
tees. Four countries needed to give additional clariﬁcation. Dif-
ferences in time frame are also remarkable: the time for receiving
an answer differed from 0 – when no notiﬁcation was needed or
no answer was foreseen – to 182 days. Table 2 gives an overview
for the 17 countries.
4.3. Right to know, right not to know
The National Academy of Science Report Human Biomonitoring
for Environmental Chemicals (NAS, 2008) supported the right to
know: “… it is better for the individual to possess this (body burden)
information than not…subjects should be told (or offered the chance
to be told) whatever researchers know (or do not know)…”. In33 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri¼CELEX:31995L0046:
en:HTML (last accessed May 14 2014).
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stated both in the EU Directive on Data Protection (art. 12) and in
the Additional Protocol to the Oviedo Convention regarding Bio-
medicine (art. 10). The Data Protection Directive does not mention
any exceptions on the right (not) to know. Article 26.1 of the
Convention however states that in exceptional circumstances, re-
strictions may be placed against the right not to know: exceptions
can be prescribed by law and are necessary in a democratic society in
the interest of public safety, for the prevention of crime, for the pro-
tection of public health or for the protection of the rights and free-
doms of others. The right not to know of the person concerned may
thus be opposed to the interest to be informed of another person
or of the public at large and these interests should be balanced by
internal law. It may also be of vital importance for an individual to
know certain facts about his/her health. But, here too it will be for
domestic law to indicate whether the doctor, in the light of the
circumstances of the particular case, may make an exception to the
right not to know. Domestic law may justify the doctor some-
times disclosing information with circumspection (“therapeutic
necessity”). In the pilot study, the informed consent forms used
allowed the study subjects to indicate their wish to know or not to
know the results. The ethics committee of one country was very
clear on the statement of overriding the right not to know in cases
of very high concentrations of toxicants. It had to be included in
the informed consent form that if concentration of toxicants were
abnormally high, this person should be re-contacted for results. In
another country, the ethical committee objected to dissemination
of the individual results to all participants and allowed only to
disseminate to individual participants with exceptionally high
values, with advice to contact their doctor.
4.4. Secondary use
Under the current regulations, the issue of reusing data can be
a very complex one to tackle, in terms of effort, time and costs,
especially if identiﬁable data is to be used. Nevertheless, a strong
call exists for more re-use of data (Miller, 2009). In the pilot studyibility of European harmonized Human Biomonitoring: Strategies
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Table 3
Overview of documents submitted to ethics committees.
Country 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Document/ English (E) Translated (T) E T E T E T E T E T E T E T E T E T E T E T E T E T E T E T E T E T
1. Submission letter X X X X X X X X X X X X X X X X X
2. Speciﬁc application form X X X X X X X X X X X X X X X X
3. Summary of the project X X X X X X X X X X X X X X X X X X X X X
4. EU protocol X X X X X X X X X X X X X X X X
5. Addition to the protocol X X X X X X X X X X
6. Policy fact sheet X X X X X X X X
7. Invitation (1st) letter X X X X X X X X X X X X X X X X X X X X X
8. Information leaﬂet X X X X X X X X X X X X X X X X X X X
9. Information leaﬂet for children X X X X X X X X X X
10. Reply card X X X X X X X X X X X
11. Reminder letter X X X X X X X X
12. Appointment (2nd) letter X X X X X X X
13. Informed Consent form X X X X X X X X X X X X X X X X X X X X X
14. Informed Assent for children X X X X X X X X X X
15. Withdrawal letter X X X X X X X X X X X
16. Letter of thanks X X X X X X X X X
17. Pre-visit (3rd) letter X X X X X X
18. Instruction leaﬂet on how to provide the urine samples X X X X X
19. Chemical fact sheets X X X X X X X X X X X
20. Letter informing on the results X X X X X X X X X X X X
21. Procedure for informing on high results X X X X
22. Basic questionnaire X X X X X X X X X X X X X X X X X X
23. Hair and urine questionnaires X X X X X X X X X X X
24. Recruitment interview X X X X X X X X X X X X
25. Non responder questionnaire X X X X X X X X X X X X X
26. Attestation of insurance X X X X X
27. Other X X X X X X X X X X X X X X X X
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the Principal Investigator (PI) in each country has to check whe-
ther the planned analyzes and the foreseen users of the data are in
line with the information as provided in the informed consent
procedure, in the submission to the ethical committee and in the
notiﬁcation to the privacy authorities. If this is the case, the full or
partial database can be transferred. If this is not the case, the PI has
to re-contact the study subjects, the ethical committees and the
privacy authorities. Exceptions to this rule exist if re-contacting
the study subject proves impossible or would involve a dis-
proportionate effort, or if recording or disclosure is expressly laid
down by law. In these cases national laws foresee appropriate
safeguards, which differ from country to country.
4.5. Lessons learned
In conclusion, the pilot study was performed on a pan-Eur-
opean scale and had to comply with dissimilar national regula-
tions and protocols. These regulations and protocols all aim to
adequately and equally protect study participants while safe-
guarding the possibility for environmental health-related studies
to progress and obtain optimal and harmonized results. Whilst it is
clear that difﬁculties, ambiguities or even inconsistencies exist in
the way ethical and juridical challenges are framed and being dealt
with, this did not cause substantial problems. The main points of
attention were to foresee a timely submission of all information so
as not to delay the start of the study and, in a further stage, to
apply correct procedures for appropriate and efﬁcient further uses
of the database.5. Conclusion
Overall the pilot study allowed (i) the development of a com-
mon study protocol, that was translated, with minor adaptations
to national situations, in 17 European countries and (ii) thePlease cite this article as: Casteleyn, L., et al., A pilot study on the feas
towards a common approach, challenges and opportunities. Environgeneration of comparable HBM data. Through a process of ex-
tensive communication and a tailor made QC system, a balance
was found between ﬂexibility and capacity building on the one
hand and a rigid structure with strict criteria on the other hand.
Although a limited number of biomarkers were measured and the
study population did not meet the requirements for representa-
tiveness, the approach allowed not only the testing of harmonized
procedures, but also to provide so-called preliminary reference
values. The results supplement those of existing studies carried
out or being carried out in several countries according to different
protocols at regional, national or transnational level and are al-
ready used for supporting and evaluating policy. Further harmo-
nization of practices in Europe and continuous exchange of capa-
cities and experiences are key elements to increase the use of HBM
for preventive policies and optimize the investments made. Ad-
ditional efforts are necessary to develop reliable biomarkers and
analytical methods and for structuring a long-term European
program. To pave the way forward despite cultural, social, legal
and ethical differences, the EU needs a structure that will allow for
suitable coordination and organization and a transparent decision-
making strategy in respect to choices to be made for the future
implementation of HBM. Reference values at European level would
give an overall view of the situation and might be the basis for
actions and policies envisaging higher environmental equity
across the EU. They can determine whether a person or group has
an unusually high exposure and identify population groups that
merit further assessment of exposure sources or health effects.
Linking with health surveys would provide considerable cost
savings and create new opportunities for research and policy as-
sessment. In an environment of funding limitations and rapid
technology advances, it is of utmost importance that data, biolo-
gical samples, and other research resources are used in the most
efﬁcient way. Enhancing transparency, multidisciplinary colla-
boration, strategic applications of new technologies and transna-
tional research are important on the way forward.ibility of European harmonized Human Biomonitoring: Strategies
. Res. (2015), http://dx.doi.org/10.1016/j.envres.2014.10.028i
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